Pharvaris is a biopharmaceutical company that develops and commercializes innovative therapies for rare diseases, with an initial focus on angioedema and other bradykinin-mediated conditions. The company's principal product candidate is deucrictibant, an oral bradykinin B2 receptor antagonist in late-stage clinical development. As a pre-commercial stage entity with no product revenues, the company funds its operations through equity financing and cash reserves, investing substantially in research and development activities including clinical trials, manufacturing, and preclinical studies conducted through partnerships with clinical research organizations and external vendors.